Impact of miRNAs involved in the STAT3 signaling pathway on esophageal cancer (Review)
- Authors:
- Ying Xiong
- Yi-Fan Liu
- Zhi-Hui Yang
- Cong-Gai Huang
-
Affiliations: School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China - Published online on: December 27, 2024 https://doi.org/10.3892/or.2024.8860
- Article Number: 27
This article is mentioned in:
Abstract
|
Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A and Smyth EC; ESMO Guidelines Committee. Electronic address, : simpleclinicalguidelines@esmo.org: Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 33:992–1004. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng H, Zhang F, Sun Y, Li S and Zhang W: Treatment options for neoadjuvant strategies of esophageal squamous cell carcinoma (Review). Mol Clin Oncol. 20:42024. View Article : Google Scholar : PubMed/NCBI | |
|
Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chung CS, Lee YC, Wang CP, Ko JY, Wang WL, Wu MS and Wang HP: Secondary prevention of esophageal squamous cell carcinoma in areas where smoking, alcohol, and betel quid chewing are prevalent. J Formos Med Assoc. 109:408–421. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A and Imamura Y: Correction to: Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 50:4252020. View Article : Google Scholar : PubMed/NCBI | |
|
Uhlenhopp DJ, Then EO, Sunkara T and Gaduputi V: Epidemiology of esophageal cancer: Update in global trends, etiology and risk factors. Clin J Gastroenterol. 13:1010–1021. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Abnet CC, Arnold M and Wei WQ: Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chu LY, Peng YH, Weng XF, Xie JJ and Xu YW: Blood-based biomarkers for early detection of esophageal squamous cell carcinoma. World J Gastroenterol. 26:1708–1725. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu CQ, Ma YL, Qin Q, Wang PH, Luo Y, Xu PF and Cui Y: Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thorac Cancer. 14:3–11. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Lv H, He Z, Wang H, Du T and Pang Z: Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication. Am J Transl Res. 8:3288–3298. 2016.PubMed/NCBI | |
|
Rui W, Li C, Da Q, Yue Y, Jing L, Ruirui G, Youbin C, Lu T and Li B: Analysis of the influencing factors in the long-term survival of esophageal cancer. Front Oncol. 13:12740142023. View Article : Google Scholar : PubMed/NCBI | |
|
Ren G, Wang Z, Tian Y, Li J, Ma Y, Zhou L, Zhang C, Guo L, Diao H, Li L, et al: Targeted chemo-photodynamic therapy toward esophageal cancer by GSH-sensitive theranostic nanoplatform. Biomed Pharmacother. 153:1135062022. View Article : Google Scholar : PubMed/NCBI | |
|
Del Valle-Morales D, Le P, Saviana M, Romano G, Nigita G, Nana-Sinkam P and Acunzo M: The Epitranscriptome in miRNAs: Crosstalk, detection, and function in cancer. Genes (Basel). 13:12892022. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Liu Z, Lin Q, Luo Q, Cen Y, Li J, Fang X and Gong C: MiRNAs and cancer: Key link in diagnosis and therapy. Genes (Basel). 12:12892021. View Article : Google Scholar : PubMed/NCBI | |
|
Zarrilli G, Galuppini F, Angerilli V, Munari G, Sabbadin M, Lazzarin V, Nicolè L, Biancotti R and Fassan M: miRNAs involved in esophageal carcinogenesis and miRNA-Related therapeutic perspectives in esophageal carcinoma. Int J Mol Sci. 22:36402021. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue J and Inazawa J: Cancer-associated miRNAs and their therapeutic potential. J Hum Genet. 66:937–945. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Saliminejad K, Khorram Khorshid HR, Soleymani Fard S and Ghaffari SH: An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 234:5451–5465. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci. 16:2628–2647. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ali Syeda Z, Langden SSS, Munkhzul C, Lee M and Song SJ: Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci. 21:17232020. View Article : Google Scholar : PubMed/NCBI | |
|
Kousar K, Ahmad T, Abduh MS, Kanwal B, Shah SS, Naseer F and Anjum S: miRNAs in regulation of tumor microenvironment, chemotherapy resistance, immunotherapy modulation and miRNA therapeutics in cancer. Int J Mol Sci. 23:138222022. View Article : Google Scholar : PubMed/NCBI | |
|
Popov A and Mandys V: Senescence-associated miRNAs and their role in pancreatic cancer. Pathol Oncol Res. 28:16101562022. View Article : Google Scholar : PubMed/NCBI | |
|
Chakrabortty A, Patton DJ, Smith BF and Agarwal P: miRNAs: Potential as biomarkers and therapeutic targets for cancer. Genes (Basel). 14:13752023. View Article : Google Scholar : PubMed/NCBI | |
|
Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M and Ghafouri-Fard S: MicroRNA: A signature for cancer progression. Biomed Pharmacother. 138:1115282021. View Article : Google Scholar : PubMed/NCBI | |
|
Haura EB, Turkson J and Jove R: Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Furtek SL, Backos DS, Matheson CJ and Reigan P: Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem Biol. 11:308–318. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rahbar Farzam O, Najafi S, Amini M, Rahimi Z, Dabbaghipour R, Zohdi O, Asemani Shahgoli G, Baradaran B and Akbari B: Interplay of miRNAs and lncRNAs in STAT3 signaling pathway in colorectal cancer progression. Cancer Cell Int. 24:162024. View Article : Google Scholar : PubMed/NCBI | |
|
Kamran MZ, Patil P and Gude RP: Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Zhu S, Shen M, Liu J, Wang M, Li C, Wang Y, Deng A and Mei Q: STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1. Carcinogenesis. 34:678–688. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan J, Zhang F and Niu R: Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep. 5:176632015. View Article : Google Scholar : PubMed/NCBI | |
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI | |
|
Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Germain D and Frank DA: Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 13:5665–5669. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Turkson J and Jove R: STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene. 19:6613–6626. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu X, Shen Y and Huang TT: Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiol Genomics. 45:1206–1214. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Li W, Liang L, Zhou Y and Li Y: The regulatory relationship between transcription factor STAT3 and noncoding RNA. Cell Mol Biol Lett. 29:42024. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kohanbash G and Okada H: MicroRNAs and STAT interplay. Semin Cancer Biol. 22:70–75. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang X, Ma HZ, Chen YQ, Zhang DZ, Ma SX, Wang HJ, Liu DM, Yuan Y and Cai H: GM-CSF-miRNA-Jak2/Stat3 signaling mediates chemotherapy-induced cancer cell stemness in gastric cancer. Front Pharmacol. 13:8553512022. View Article : Google Scholar : PubMed/NCBI | |
|
Sajjadi-Dokht M, Merza Mohamad TA, Sulaiman Rahman H, Suliman Maashi M, Danshina S, Shomali N, Solali S, Marofi F, Zeinalzadeh E, Akbari M, et al: MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers. Genes Dis. 9:849–867. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ma RJ, Ma C, Hu K, Zhao MM, Zhang N and Sun ZG: Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review). Int J Oncol. 61:1052022. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Qin X, Bian W, Li Y, Shan B, Yao Z and Li S: Exosomal lncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis. J Exp Clin Cancer Res. 38:4772019. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y, Li Y, Nian Y, Liu D, Dai F and Zhang J: STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells. BMC Cancer. 15:3062015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Ma K, Yang S, Zhang X, Wang F, Zhang X, Liu H and Fan Q: MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol. 53:644–658. 2018.PubMed/NCBI | |
|
Wang ZZ, Luo YR, Du J, Yu Y, Yang XZ, Cui YJ and Jin XF: MiR-296-5p inhibits cell invasion and migration of esophageal squamous cell carcinoma by downregulating STAT3 signaling. Eur Rev Med Pharmacol Sci. 23:5206–5214. 2019.PubMed/NCBI | |
|
Yuan RB, Zhang SH, He Y, Zhang XY and Zhang YB: MiR-874-3p is an independent prognostic factor and functions as an anti-oncomir in esophageal squamous cell carcinoma via targeting STAT3. Eur Rev Med Pharmacol Sci. 22:7265–7273. 2018.PubMed/NCBI | |
|
Zang HL, Ji FJ, Ju HY and Tian XF: Circular RNA AKT3 governs malignant behaviors of esophageal cancer cells by sponging miR-17-5p. World J Gastroenterol. 27:240–254. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Z, Tie X, Li N, Yi Z, Shen F and Zhang Y: Circular RNA hsa_circ_0000654 promotes esophageal squamous cell carcinoma progression by regulating the miR-149-5p/IL-6/STAT3 pathway. IUBMB Life. 72:426–439. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Meng L, Wang F, Sun S, Zheng Y, Ding Z, Sun Y, Li B, Meng Q and Xu M: MicroRNA-30b targets CBX3 and regulates cell proliferation, apoptosis, and migration in esophageal squamous cell carcinoma via the JAK2/STAT3 signaling pathway. Int J Clin Exp Pathol. 10:11828–11837. 2017.PubMed/NCBI | |
|
Ke S, Fang M, Li R, Wang J and Lu J: Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis. Bioengineered. 13:12998–13010. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Hu X, Wu Y, Cong L, He X, Lu J, Feng J and Liu D: Long non-coding RNA XIST promotes the development of esophageal cancer by sponging miR-494 to regulate CDK6 expression. Biomed Pharmacother. 109:2228–2236. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Chen XW, Song XJ, Du HY and Si FC: Baitouweng decoction suppresses growth of esophageal carcinoma cells through miR-495-3p/BUB1/STAT3 axis. World J Gastrointest Oncol. 16:3193–3210. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Han Y, Fan X, Fan L, Wu Y, Zhou Z, Wang G, Guo L, Gao W, Chen Y and Gao Q: Liujunzi decoction exerts potent antitumor activity in oesophageal squamous cell carcinoma by inhibiting miR-34a/STAT3/IL-6R feedback loop, and modifies antitumor immunity. Phytomedicine. 111:1546722023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Wu G and Han Y, Li X, Feng X, Wang H, Zhang L, Lin M, Cai Y and Han Y: miR-124 regulates STAT3-mediated cell proliferation, migration and apoptosis in bladder cancer. Oncol Lett. 16:5875–5881. 2018.PubMed/NCBI | |
|
Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y, Wang K and Wan J: MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS One. 8:e703002013. View Article : Google Scholar : PubMed/NCBI | |
|
Lu Y, Yue X, Cui Y, Zhang J and Wang K: MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun. 441:873–879. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen M, Ye X, Wang R and Poon K: Research progress of cancer stem cells and IL-6/STAT3 signaling pathway in esophageal adenocarcinoma. Transl Cancer Res. 9:363–371. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lin H, Lian J, Xia L, Guan G and You J: CBX3 promotes gastric cancer progression and affects factors related to immunotherapeutic responses. Cancer Manag Res. 12:10113–10125. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang K, Wang YL, Zhu Z, Cao XH, Liang MX, Xu D, Fei YJ, Yang SY, Zhou HL and Tang JH: CBX3 promotes breast cancer progression and high level of CBX3 predicts poor prognosis in patients. Neoplasma. 70:71–81. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen LY, Cheng CS, Qu C, Wang P, Chen H, Meng ZQ and Chen Z: CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Biochem Biophys Res Commun. 500:691–697. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou C, Fan N, Liu F, Fang N, Plum PS, Thieme R, Gockel I, Gromnitza S, Hillmer AM, Chon SH, et al: Linking cancer stem cell plasticity to therapeutic resistance-mechanism and novel therapeutic strategies in esophageal cancer. Cells. 9:14812020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang B, Lang X and Li X: The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol. 12:10231772022. View Article : Google Scholar : PubMed/NCBI | |
|
Mengie Ayele T, Tilahun Muche Z, Behaile Teklemariam A, Bogale Kassie A and Chekol Abebe E: Role of JAK2/STAT3 signaling pathway in the tumorigenesis, chemotherapy resistance, and treatment of solid tumors: A systemic review. J Inflamm Res. 15:1349–1364. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Fassl A, Geng Y and Sicinski P: CDK4 and CDK6 kinases: From basic science to cancer therapy. Science. 375:eabc14952022. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang H, Guo Y, Huang K, Lu R, Peng X and Lin S: MicroRNA-34a inhibits esophageal squamous cell carcinoma progression by targeting E2F5. J Buon. 24:2514–2522. 2019.PubMed/NCBI | |
|
Ye Z, Xie T, Yan F, Wang L, Fang J, Wang Z, Hu F, Wang F and Fu Z: MiR-34a reverses radiation resistance on ECA-109 cells by inhibiting PI3K/AKT/mTOR signal pathway through downregulating the expression of SIRT1. Int J Radiat Biol. 97:452–463. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yang L, Song X, Zhu J, Li M, Ji Y, Wu F, Chen Y, Cui X, Hu J, Wang L, et al: Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. Int J Oncol. 51:378–388. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nie J, Ge X, Geng Y, Cao H, Zhu W, Jiao Y, Wu J, Zhou J and Cao J: miR-34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1. Oncol Rep. 34:311–317. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Meng X and Li M: MiR-126 promotes esophageal squamous cell carcinoma via inhibition of apoptosis and autophagy. Aging (Albany NY). 12:12107–12118. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Tian H, Li R, Yan W and Xu R: MicroRNA-4286 promotes esophageal carcinoma development by targeting INPP4A to evoke the JAK2/STAT3 pathway activation. Pharmazie. 73:342–348. 2018.PubMed/NCBI | |
|
Wang H, Peng D, Gan M, He Z and Kuang Y: CPEB3 overexpression caused by miR-106b-5p inhibition inhibits esophageal carcinoma in-vitro progression and metastasis. Anticancer Drugs. 33:335–351. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Xu DD, Zhou PJ, Wang Y, Zhang L, Fu WY, Ruan BB, Xu HP, Hu CZ, Tian L, Qin JH, et al: Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway. Mol Cancer. 15:402016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Lu W, Chen Y, Lin Y, Yang X, Wang H and Liu Z: The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma. Mol Oncol. 15:1566–1583. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kong R, Ma Y, Feng J, Li S, Zhang W, Jiang J, Zhang J, Qiao Z, Yang X and Zhou B: The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A. Cell Mol Biol Lett. 21:32016. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR-126 in esophageal squamous cell carcinoma. Oncol Rep. 32:1225–1233. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nie ZC, Weng WH, Shang YS, Long Y, Li J, Xu YT and Li Z: MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway. Int J Clin Exp Pathol. 8:4745–4754. 2015.PubMed/NCBI | |
|
Liu R, Gu J, Jiang P, Zheng Y, Liu X, Jiang X, Huang E, Xiong S, Xu F, Liu G, et al: DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res. 21:854–863. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gu JF, Liu SG, Pan Q, Qin F and Li YY: Negative regulation of CDK6 expression by microRNA-126-5p and its influence on the proliferation and invasion of esophageal cancer cells. Anat Rec (Hoboken). 303:2811–2820. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Drahos J, Schwameis K, Orzolek LD, Hao H, Birner P, Taylor PR, Pfeiffer RM, Schoppmann SF and Cook MB: MicroRNA profiles of Barrett's esophagus and esophageal adenocarcinoma: Differences in glandular non-native epithelium. Cancer Epidemiol Biomarkers Prev. 25:429–437. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng Q, Zhu Z, Song L and He Z: Transferred by exosomes-derived MiR-19b-3p targets PTEN to regulate esophageal cancer cell apoptosis, migration and invasion. Biosci Rep. 40:BSR202018582020. View Article : Google Scholar : PubMed/NCBI | |
|
Chiam K, Mayne GC, Wang T, Watson DI, Irvine TS, Bright T, Smith LT, Ball IA, Bowen JM, Keefe DM, et al: Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus. World J Gastroenterol. 26:2570–2583. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pandey P, Suyal G, Aprajita Pasbola K and Sharma R: NGS-based profiling identifies miRNAs and pathways dysregulated in cisplatin-resistant esophageal cancer cells. Funct Integr Genomics. 23:1112023. View Article : Google Scholar : PubMed/NCBI | |
|
Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M and Doki Y: Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res. 18:5144–5153. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Q, Huang L, Qin G, Qiao Y, Ren F, Shen C, Wang S, Liu S, Lian J, Wang D, et al: Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 518:35–48. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen K, Wang X, Yang L and Chen Z: The Anti-PD-1/PD-L1 immunotherapy for gastric esophageal cancer: A systematic review and meta-analysis and literature review. Cancer Control. 28:10732748219974302021. View Article : Google Scholar : PubMed/NCBI |
